N-(3-morpholinopropyl)-4-iodobenzenesulphonamide | 403793-23-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-morpholinopropyl)-4-iodobenzenesulphonamide
• 英文别名: 4-iodo-N-(3-morpholin-4-ylpropyl)benzenesulfonamide
• CAS: 403793-23-7
• 化学式: C₁₃H₁₉IN₂O₃S
• 分子量: 410.276
• InChiKey: WEFGQYOIWCQPST-UHFFFAOYSA-N

物化性质

• 沸点：
  491.0±55.0 °C(Predicted)
• 密度：
  1.579±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  20
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  67
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N-(3-氨丙基)吗啉 、 4-碘苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以100%的产率得到N-(3-morpholinopropyl)-4-iodobenzenesulphonamide
  参考文献：
  名称：

  Imidazolo-5-YL-2anilino-pyrimidines as agents for the inhibition of the cell proliffration

  摘要：

  该公式化合物（I）：其中R1、R2、R3、R4、R5、R6、p、q和n的定义如下，并描述了其药用盐和体内可水解酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为用于在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）作用的药物。

  公开号：

  US20040014776A1

文献信息

• Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
  申请人：Breault Anne Gloria

  公开号：US20060004033A1

  公开（公告）日：2006-01-05

  Compounds of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , p, q, and n are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  式(I)的化合物：其中R1、R2、R3、R4、R5、R6、p、q和n的定义如内部所述，并且所述化合物的药学上可接受的盐和体内可水解的酯被描述。还描述了它们的制备过程以及它们作为药物的用途，特别是作为在温血动物（如人）中产生细胞周期抑制（抗细胞增殖）效应的药物。
• Imidazolo-5-YL-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation
  申请人：Breault Gloria Anne

  公开号：US06969714B2

  公开（公告）日：2005-11-29

  Compounds of the formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , p, q, and n are as defined within and a pharmaceutically acceptable salts and in vivo hydrolysable esters are described. Also described are processes for their preparation and their use as medicaments, particularly medicaments for producing a cell cycle inhibitory (anti-cell-proliferation) effect in a warm-blooded animal, such as man.

  该式(I)的化合物：其中R1、R2、R3、R4、R5、R6、p、q和n的定义如内部所述，并描述了其药学上可接受的盐和体内可水解的酯。还描述了它们的制备过程以及它们作为药物的用途，特别是作为制造细胞周期抑制（抗细胞增殖）效应的药物，用于温血动物，例如人类。
• Pharmaceutical composition containing a heterocyclic modulator of ATP-binding cassette transporters.
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP2395002A1

  公开（公告）日：2011-12-14

  Pharmaceutically acceptable compositions of the present invention are useful as modulators of ATP-Binding Cassette ("ABC") transporters of fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ("CFTR").

  本发明的药学上可接受的组合物可用作 ATP 结合盒（"ABC"）转运体及其片段的调节剂，包括囊性纤维化跨膜传导调节器（"CFTR"）。
• Modulators of ATP-binding cassette transporters
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US10626111B2

  公开（公告）日：2020-04-21

  Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTC”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

  本发明的化合物及其药学上可接受的组合物可用作 ATP 结合盒（"ABC"）转运体或其片段（包括囊性纤维化跨膜传导调节剂（"CFTC"））的调节剂。本发明还涉及使用本发明化合物治疗 ABC 转运体介导的疾病的方法。
• IMIDAZOLO-5-YL-2-ANILINO-PYRIMIDINES AS AGENTS FOR THE INHIBITION OF THE CELL PROLIFERATION
  申请人：AstraZeneca AB

  公开号：EP1351958B1

  公开（公告）日：2004-06-16